Revolution Medicines Shares Jump 11% as $28–32B Buyout Talks With Merck Surface
Revolution Medicines shares jumped 11% after the Financial Times reported it is in buyout talks with Merck and other major pharmaceutical firms. Sources indicated the proposed acquisition price ranges from $28 billion to $32 billion, highlighting strong M&A interest in the oncology-focused biotech.
1. Takeover Speculation Spurs Double-Digit Gain
Shares of Revolution Medicines surged by approximately 11% on Friday following a Financial Times report that the company is in buyout discussions with a major pharmaceutical peer. The report, citing unnamed sources, indicated that the suitor is negotiating a purchase price in the range of $28 billion to $32 billion. On the day of the report, trading volume reached 969,000 shares, compared with an average daily volume of 2.7 million, reflecting heightened investor interest in the takeover narrative.
2. Strategic Appeal of Oncology Pipeline
Revolution Medicines has built a robust oncology portfolio centered on RAS [ON] inhibitor programs, most notably its lead asset, daraxonrasib. The company’s phase 3 RASolute-302 trial in metastatic pancreatic cancer patients with RAS mutations is a critical catalyst, with topline data expected in 2026. Analysts point to the trial’s potential to address an unmet need and to drive significant revenue upside if clinical endpoints are met, underpinning the company’s multibillion-dollar valuation.
3. Market Capitalization and M&A Dynamics
At a market capitalization of roughly $21 billion, Revolution Medicines represents an attractive asset for larger pharmaceutical firms seeking to replenish pipelines ahead of looming patent expirations. In addition to the reported discussions with one industry titan, other unnamed bidders are said to be evaluating offers. Should a deal materialize, investors could expect a substantial takeover premium, given the gap between the current market value and the indicative bid range.